Changfa Xia,He Li,Chen Wu et al.
Changfa Xia et al.
China accounts for nearly 17% of the global population yet contributes approximately 25% of the global cancer burden with >5 million new cancers diagnosed every year; this evolving landscape is reshaping the global pattern of cancer burden....
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges [0.03%]
抗体-药物偶联物在妇科肿瘤中的机遇与挑战
Kathleen N Moore,Oladapo O Yeku,Brooke E Howitt et al.
Kathleen N Moore et al.
Antibody-drug conjugates (ADCs) have transformed the cancer therapeutic landscape over the past two decades, profoundly shaping treatment outcomes across a wide array of indications. Three ADCs are currently approved for previously treated ...
New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer [0.03%]
新的标准和限制条件重新定义了铂耐药性卵巢癌的治疗顺序
Isabelle Ray-Coquard,Kathleen N Moore
Isabelle Ray-Coquard
Diana Romero
Diana Romero
Peter Sidaway
Peter Sidaway
From ASCO 2026 [0.03%]
2026年ASCO年会亮点
David Killock
David Killock
Peter Sidaway
Peter Sidaway
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement [0.03%]
欧洲肝脏研究协会/美国肝病研究协会/国际肝癌协会关于肝细胞癌的试验设计和终点声明共识陈述
Josep M Llovet,Ezequiel Mauro,Lorenza Rimassa et al.
Josep M Llovet et al.
The management of hepatocellular carcinoma (HCC) has undergone radical change over the past decade. Immunotherapies now dominate the treatment of advanced-stage disease and are increasingly being evaluated in perioperative and intermediate-...